SCHEMBL23979330

SCHEMBL23979330

CC(C)(C)C(=O)CCc1cccc(C(C)(C)C)c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.45
CYP24A1 Q07973 1/20 0.43
HDAC4 P56524 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
RXRA P19793 2/20 0.42
RXRB P28702 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP1A2 P05177 1/20 0.42
RXRG P48443 1/20 0.42
FFAR4 Q5NUL3 1/20 0.40
CCR9 P51686 1/20 0.40
NR1H4 Q96RI1 2/20 0.39
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
BCHE P06276 2/20 0.39
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
MRGPRX4 Q96LA9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12993133 0.85 RXRA (0.58) ACHERXRARXRBCYP2C19CYP1A2
SCHEMBL15032898 0.85 ALDH1A1 (0.56) ACHEHDAC4HDAC2HDAC8RXRA
SCHEMBL12993402 0.83 CYP1A2 (0.45) ACHEHDAC4HDAC2HDAC8RXRA
SCHEMBL23979331 0.83 CYP1A2 (0.51) ACHEHDAC4HDAC2HDAC8RXRA
SCHEMBL19169511 0.81 DRD2 (0.50) CYP24A1
SCHEMBL12993003 0.81 SIRT2 (0.49) ACHEHDAC4HDAC2HDAC8CYP2C19
SCHEMBL12993335 0.81 CYP2C19 (0.46) ACHEHDAC4HDAC2HDAC8CYP2C19
SCHEMBL12993388 0.81 KMT2A (0.44) ACHEHDAC4HDAC2HDAC8RXRA
SCHEMBL11203907 0.80 MAOA (0.50) CYP24A1
SCHEMBL26343269 0.80 TAAR1 (0.49) CYP24A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210338670-A1 NON-INVASIVE PET IMAGING OF CDK4/6 ACTIVATION IN CANCER NEW YORK UNIVERSITY 2021-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210338670-A1 NON-INVASIVE PET IMAGING OF CDK4/6 ACTIVATION IN CANCER CDK4, CDK6, CDKL4 ACHE 4099/4885CYP24A1 1557/4885HDAC4 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.